Hepatitis D Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type (Acute, Chronic), By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others), By Region and Competition, 2019-2029F

  • Industry : Healthcare
  • Pages : NA
  • Published Date : NA
Customization Enquiry

Buy Now

Main Content start here

Summary

Report Description

Forecast Period

2025-2029

Market Size (2023)

USD 1.11 Billion

CAGR (2024-2029)

5.25%

Fastest Growing Segment

Chronic

Largest Market

North America

Market Size (2029)

USD 1.51 Billion


Market Overview

Global Hepatitis D Market was valued at USD 1.11 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Hepatitis D, also known as delta hepatitis, is a serious liver infection caused by the hepatitis D virus (HDV). It is considered one of the most severe forms of viral hepatitis, often complicating the course of hepatitis B infection. With millions of people affected worldwide, the global hepatitis D market plays a crucial role in addressing the medical needs of patients, driving research and development efforts, and shaping healthcare policies. The global hepatitis D market encompasses various segments, including diagnostics, therapeutics, and vaccines. Diagnostic tests for hepatitis D typically involve serological assays to detect specific antibodies or antigens associated with HDV infection. Therapeutic interventions mainly focus on managing symptoms, reducing liver inflammation, and preventing disease progression. Currently, there are no specific antiviral treatments approved for hepatitis D, although several investigational drugs are under development. Additionally, efforts to develop an effective hepatitis D vaccine are ongoing, aiming to provide long-term protection against HDV infection.

Key Market Drivers

Increasing Prevalence of Hepatitis D is Driving the Global Hepatitis D Market

Hepatitis, a viral infection causing inflammation of the liver, continues to be a significant public health concern worldwide. Among the various forms of hepatitis, hepatitis B and hepatitis D infections are particularly concerning due to their chronic nature and potential for severe liver damage. In recent years, the increasing prevalence of hepatitis B has been a key driver behind the growth of the global hepatitis D market. Hepatitis B virus (HBV) infection remains a major global health problem, with an estimated 292 million people living with chronic HBV infection globally. The virus is highly contagious and can be transmitted through contact with infected blood or bodily fluids. Inadequate vaccination coverage, unsafe injection practices, and lack of awareness contribute to the ongoing transmission of the virus in many parts of the world.

Hepatitis D virus (HDV) is a defective virus that requires the presence of HBV to replicate. Individuals infected with HBV can also become co-infected with HDV, leading to what is known as hepatitis D or delta hepatitis. Hepatitis D infection can occur either simultaneously with acute HBV infection (co-infection) or in individuals with chronic HBV infection (superinfection). HDV infection is associated with more severe liver disease outcomes compared to HBV infection alone, including higher rates of cirrhosis and liver failure.

Growing Awareness and Screening Programs is Driving the Global Hepatitis D Market

In recent years, there has been a concerted effort to raise awareness about hepatitis D among healthcare professionals, policymakers, and the general public. Governments, non-profit organizations, and healthcare agencies have been actively involved in educational campaigns to highlight the risks associated with hepatitis D infection and the importance of screening, vaccination, and treatment.

One of the key drivers behind the growing awareness of hepatitis D is the implementation of screening programs in high-risk populations. These programs target individuals who are at increased risk of hepatitis D infection, such as those living with chronic hepatitis B, injecting drug users, and individuals from endemic regions where hepatitis D prevalence is high.

Through these screening programs, healthcare providers can identify individuals who are co-infected with hepatitis D and hepatitis B, enabling timely intervention and management. Early detection of hepatitis D infection is crucial for preventing disease progression and reducing the risk of complications.

Advancements in diagnostic technologies have also played a significant role in driving the global hepatitis D market. Newer diagnostic tests, including molecular assays and serological tests, offer improved sensitivity and specificity for detecting hepatitis D infection. These tests allow for accurate diagnosis and monitoring of hepatitis D patients, facilitating better treatment outcomes. While there is currently no specific antiviral therapy approved for the treatment of hepatitis D, research efforts are underway to develop targeted therapies that can effectively suppress HDV replication. Several clinical trials are ongoing to evaluate the safety and efficacy of novel antiviral agents and immune modulators for the management of hepatitis D. In addition to antiviral therapy, management of hepatitis D often involves supportive care to address liver-related complications and optimize liver function. Liver transplantation may be considered in severe cases of hepatitis D-related liver failure.


Download Free Sample Report

Key Market Challenges

Diagnostic Complexity:

Accurate diagnosis of hepatitis D relies on specialized laboratory tests, including serological assays and molecular techniques. However, the complexity and cost of these diagnostic methods pose significant challenges, particularly in resource-limited settings where access to advanced healthcare infrastructure and trained personnel may be limited. Simplifying diagnostic algorithms and promoting the development of affordable point-of-care tests are essential steps toward improving diagnostic capabilities globally.

Lack of Specific Treatment Options

Unlike hepatitis B or C, there are currently no approved antiviral therapies specifically targeting hepatitis D. Treatment options for hepatitis D are limited and primarily focus on managing symptoms and preventing disease progression. The absence of targeted therapies underscores the urgent need for innovative research and development efforts aimed at identifying novel therapeutic targets and exploring potential treatment modalities.

Key Market Trends 

Technological Advancements

Technological advancements have been revolutionizing various sectors of the healthcare industry, and one area where this progress is particularly evident is in the field of Hepatitis D. Hepatitis D, caused by the hepatitis delta virus (HDV), is a serious liver infection that affects millions of people worldwide. With growing awareness and advancements in technology, the global Hepatitis D market is witnessing significant growth. One of the key drivers of growth in the Hepatitis D market is the development of advanced diagnostic tools. Traditionally, diagnosing Hepatitis D has been challenging due to its overlapping symptoms with other forms of hepatitis. However, with the advent of molecular diagnostic techniques such as polymerase chain reaction (PCR) and nucleic acid amplification tests (NAATs), healthcare providers can now accurately detect HDV RNA in patient samples. These tools not only enable early diagnosis but also help in monitoring disease progression and treatment efficacy, thereby driving market growth.

Another significant factor contributing to the growth of the Hepatitis D market is the emergence of improved treatment options. Historically, treatment for Hepatitis D has been limited, with interferon-based therapies being the primary option. However, advancements in drug development have led to the introduction of novel therapeutics targeting various stages of the HDV lifecycle. These include entry inhibitors, RNA interference agents, and host-targeting antivirals, offering new hope for patients with Hepatitis D and driving market expansion.

The rise of telemedicine and remote monitoring technologies has also played a crucial role in driving the Hepatitis D market. Telemedicine allows patients to consult with healthcare providers remotely, eliminating geographical barriers and improving access to care, especially in underserved areas. Additionally, remote monitoring technologies enable healthcare providers to remotely track patients' liver function tests, viral load levels, and medication adherence, facilitating timely interventions and improving patient outcomes.

Artificial intelligence (AI) and machine learning (ML) algorithms are increasingly being integrated into Hepatitis D research and clinical practice, further propelling market growth. These technologies enable the analysis of large datasets, such as genomic data and medical imaging scans, to identify patterns, predict disease progression, and personalize treatment plans. AI-powered diagnostic tools can also assist healthcare providers in interpreting test results more accurately and efficiently, leading to improved patient management and outcomes.

Segmental Insights

Type Insights

Based on the category of type, Chronic emerged as the dominant segment in the global market for Hepatitis D in 2023. Chronic hepatitis D poses significant long-term health risks, including liver cirrhosis, liver cancer, and liver failure. As a result, patients with chronic hepatitis D require ongoing medical monitoring and management, leading to a higher demand for healthcare services and treatments.

Compared to other forms of hepatitis, such as hepatitis B and C, treatment options for hepatitis D are limited. Interferon-based therapies have been the mainstay of treatment for chronic hepatitis D, but they are often associated with adverse side effects and limited efficacy. The lack of highly effective and well-tolerated treatments underscores the importance of developing new therapies specifically targeting chronic hepatitis D.

Diagnosis Insights

The Blood Tests segment is projected to experience rapid growth during the forecast period. Blood tests, such as serological assays and nucleic acid tests (NATs), offer high sensitivity and specificity in detecting markers of hepatitis D infection. These tests can accurately identify the presence of HDV antigens and antibodies in blood samples, enabling reliable diagnosis.

Blood tests are relatively non-invasive and can be performed using standard laboratory equipment. Patients can undergo blood testing at healthcare facilities, clinics, or diagnostic laboratories, making it a convenient option for screening and diagnosis.

Many blood tests for hepatitis D diagnosis have received regulatory approvals from health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These approvals validate the accuracy and reliability of blood-based diagnostic assays, instilling confidence among healthcare providers and patients. Ongoing advancements in laboratory technology have led to the development of more sensitive and efficient blood tests for hepatitis D. Innovations such as real-time polymerase chain reaction (PCR) and next-generation sequencing (NGS) have enhanced the detection capabilities of blood-based assays, further solidifying their dominance in the market.


Download Free Sample Report

Regional Insights

North America emerged as the dominant region in the global Hepatitis D market in 2023, holding the largest market share in terms of value. North America boasts of advanced healthcare infrastructure, including state-of-the-art medical facilities, research institutions, and pharmaceutical companies. This infrastructure facilitates early diagnosis, treatment, and research in hepatitis D, thereby driving market growth.

Recent Developments

  • In June 2023, Gilead Sciences has released encouraging findings from an advanced study of its Hepcludex (bulevirtide) treatment for chronic hepatitis D virus (HDV). According to Gilead, the latest 96-week data from the phase 3 MYR301 trial, presented at this year's European Association for the Study of the Liver Congress, confirms Hepcludex's effectiveness and tolerability in managing chronic HDV. The data demonstrates a steady increase in combined virological and biochemical response rates up to week 96, with rates reaching 55% and 56% at the 2mg and 10mg dose levels, respectively.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • NanoGen Healthcare Pvt. Ltd.
  • PROBIOMED SA de CV
  • 3SBio Group
  • Hepion Pharmaceuticals, Inc.
  • Antios Therapeutics, Inc.
  • PharmaEssentia Corporation
  • Replicor
  • Apotex Corp.
  • Mylan N.V
  • Aurobindo Pharma Limited
  • Gilead Sciences, Inc.

By Type

By Diagnosis

By Region
  • Acute
  • Chronic
  • Blood Tests
  • Elastography
  • Liver Biopsy
  • Serologic Testing
  • Others
  • North America
  • Europe
  • Asia Pacific
  • South America
  • Middle East & Africa

 

Report Scope:

In this report, the Global Hepatitis D Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

  • Hepatitis D Market, By Type:

o   Acute

o   Chronic

  • Hepatitis D Market, By Diagnosis:

o   Blood Tests

o   Elastography

o   Liver Biopsy

o   Serologic Testing

o   Others

  • Hepatitis D Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia-Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Hepatitis D Market.

Available Customizations:

Global Hepatitis D market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Global Hepatitis D Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]  

Table of content

1.    Product Overview

1.1.  Market Definition

1.2.  Scope of the Market

1.2.1.     Markets Covered

1.2.2.     Years Considered for Study

1.2.3.     Key Market Segmentations

2.    Research Methodology

2.1.  Objective of the Study

2.2.  Baseline Methodology

2.3.  Key Industry Partners

2.4.  Major Association and Secondary Sources

2.5.  Forecasting Methodology

2.6.  Data Triangulation & Validation

2.7.  Assumptions and Limitations

3.    Executive Summary

3.1.  Overview of the Market

3.2.  Overview of Key Market Segmentations

3.3.  Overview of Key Market Players

3.4.  Overview of Key Regions/Countries

3.5.  Overview of Market Drivers, Challenges, Trends

4.    Global Hepatitis D  Market Outlook

4.1.  Market Size & Forecast

4.1.1.     By Value

4.2.  Market Share & Forecast

4.2.1.     By Type (Acute, Chronic)

4.2.2.     By Diagnosis (Blood Tests, Elastography, Liver Biopsy, Serologic Testing, Others)

4.2.3.     By Region

4.2.4.     By Company (2023)

4.3.  Market Map

4.3.1.     By Type

4.3.2.     By Diagnosis

4.3.3.     By Region

5.    Asia Pacific Hepatitis D  Market Outlook

5.1.  Market Size & Forecast

5.1.1.     By Value

5.2.  Market Share & Forecast

5.2.1.     By Type

5.2.2.     By Diagnosis

5.2.3.     By Country

5.3.  Asia Pacific: Country Analysis

5.3.1.     China Hepatitis D  Market Outlook

5.3.1.1.         Market Size & Forecast

5.3.1.1.1.             By Value

5.3.1.2.         Market Share & Forecast

5.3.1.2.1.             By Type

5.3.1.2.2.             By Diagnosis

5.3.2.     India Hepatitis D  Market Outlook

5.3.2.1.         Market Size & Forecast

5.3.2.1.1.             By Value

5.3.2.2.         Market Share & Forecast

5.3.2.2.1.             By Type

5.3.2.2.2.             By Diagnosis

5.3.3.     Australia Hepatitis D  Market Outlook

5.3.3.1.         Market Size & Forecast

5.3.3.1.1.             By Value

5.3.3.2.         Market Share & Forecast

5.3.3.2.1.             By Type

5.3.3.2.2.             By Diagnosis

5.3.4.     Japan Hepatitis D  Market Outlook

5.3.4.1.         Market Size & Forecast

5.3.4.1.1.             By Value

5.3.4.2.         Market Share & Forecast

5.3.4.2.1.             By Type

5.3.4.2.2.             By Diagnosis

5.3.5.     South Korea Hepatitis D  Market Outlook

5.3.5.1.         Market Size & Forecast

5.3.5.1.1.             By Value

5.3.5.2.         Market Share & Forecast

5.3.5.2.1.             By Type

5.3.5.2.2.             By Diagnosis

6.    Europe Hepatitis D  Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type

6.2.2.     By Diagnosis

6.2.3.     By Country

6.3.  Europe: Country Analysis

6.3.1.     France Hepatitis D  Market Outlook

6.3.1.1.         Market Size & Forecast

6.3.1.1.1.             By Value

6.3.1.2.         Market Share & Forecast

6.3.1.2.1.             By Type

6.3.1.2.2.             By Diagnosis

6.3.2.     Germany Hepatitis D  Market Outlook

6.3.2.1.         Market Size & Forecast

6.3.2.1.1.             By Value

6.3.2.2.         Market Share & Forecast

6.3.2.2.1.             By Type

6.3.2.2.2.             By Diagnosis

6.3.3.     Spain Hepatitis D  Market Outlook

6.3.3.1.         Market Size & Forecast

6.3.3.1.1.             By Value

6.3.3.2.         Market Share & Forecast

6.3.3.2.1.             By Type

6.3.3.2.2.             By Diagnosis

6.3.4.     Italy Hepatitis D  Market Outlook

6.3.4.1.         Market Size & Forecast

6.3.4.1.1.             By Value

6.3.4.2.         Market Share & Forecast

6.3.4.2.1.             By Type

6.3.4.2.2.             By Diagnosis

6.3.5.     United Kingdom Hepatitis D  Market Outlook

6.3.5.1.         Market Size & Forecast

6.3.5.1.1.             By Value

6.3.5.2.         Market Share & Forecast

6.3.5.2.1.             By Type

6.3.5.2.2.             By Diagnosis

7.    North America Hepatitis D  Market Outlook

7.1.  Market Size & Forecast

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.2.     By Diagnosis

7.2.3.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Hepatitis D  Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.2.             By Diagnosis

7.3.2.     Mexico Hepatitis D  Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.2.             By Diagnosis

7.3.3.     Canada Hepatitis D  Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.2.             By Diagnosis

8.    South America Hepatitis D  Market Outlook

8.1.  Market Size & Forecast

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.2.     By Diagnosis

8.2.3.     By Country

8.3.  South America: Country Analysis

8.3.1.     Brazil Hepatitis D  Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.2.             By Diagnosis

8.3.2.     Argentina Hepatitis D  Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.2.             By Diagnosis

8.3.3.     Colombia Hepatitis D  Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.2.             By Diagnosis

9.    Middle East and Africa Hepatitis D  Market Outlook

9.1.  Market Size & Forecast

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Diagnosis

9.2.3.     By Country

9.3.  MEA: Country Analysis

9.3.1.     South Africa Hepatitis D  Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Diagnosis

9.3.2.     Saudi Arabia Hepatitis D  Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Diagnosis

9.3.3.     UAE Hepatitis D  Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Diagnosis

10.  Market Dynamics

10.1.    Drivers

10.2.    Challenges

11.  Market Trends & Developments

11.1.    Recent Developments

11.2.    Product Launches

11.3.    Mergers & Acquisitions

12.  Global Hepatitis D  Market: SWOT Analysis

13.  Porter’s Five Forces Analysis

13.1.    Competition in the Industry

13.2.    Potential of New Entrants

13.3.    Power of Suppliers

13.4.    Power of Customers

13.5.    Threat of Substitute Product 

14.  Competitive Landscape

14.1.    F. Hoffmann-La Roche Ltd

14.1.1.           Company Snapshot

14.1.2.           Product & Services

14.1.3.           Financials (In case of listed)

14.1.4.           Recent Developments

14.1.5.           SWOT Analysis

14.2.    NanoGen Healthcare Pvt. Ltd.

14.3.    PROBIOMED SA de CV

14.4.    3SBio Group

14.5.    Hepion Pharmaceuticals, Inc.

14.6.    Antios Therapeutics, Inc.

14.7.  PharmaEssentia Corporation

14.8.  Replicor

14.9.  Apotex Corp.

14.10.  Mylan N.V

14.11.  Aurobindo Pharma Limited

14.12.  Gilead Sciences, Inc.

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Frequently asked questions

down-arrow

The market size of the Global Hepatitis D Market was estimated to be USD 1.11 Billion in 2023.

down-arrow

The global Hepatitis D market faces several significant challenges that impact its development and accessibility. Hepatitis D is relatively rare compared to other forms of hepatitis. There is often a lack of awareness among the general public and healthcare providers about the disease, which can result in delayed diagnosis or misdiagnosis. Improved screening strategies are needed to identify cases more effectively.

down-arrow

F. Hoffmann-La Roche Ltd , NanoGen Healthcare Pvt. Ltd., PROBIOMED SA de CV, 3SBio Group, Hepion Pharmaceuticals, Inc., Antios Therapeutics, Inc., PharmaEssentia Corporation, Replicor, Apotex Corp., Mylan N.V, Aurobindo Pharma Limited, Gilead Sciences, Inc. were the top players operating in the Global Hepatitis D Market in 2023.

down-arrow

Increasing prevalence of Hepatitis D and growing awareness and screening programs are the major drivers for the Global Hepatitis D Market.

Related Reports

profile

Sakshi Bajaal

Business Consultant
Press Release

Hepatitis D Market to Grow with a CAGR of 5.25% through 2029

Apr, 2024

Increasing prevalence of Hepatitis D and growing awareness and screening programs are factors driving the Global Hepatitis D Market in the forecast period 2025-2029.

Why Choose Us